Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Egfr Tyrosine Kinase Inhibitor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 0 results

Early research (Phase 1)Study completedNCT02191891
What this trial is testing

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 32
Testing effectiveness (Phase 2)Study completedNCT03543683
What this trial is testing

Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

Who this might be right for
Non-Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVEGFR T790M
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 115
Testing effectiveness (Phase 2)UnknownNCT03257124
What this trial is testing

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS

Who this might be right for
Non-Small Cell Lung Cancer With EGFR T790M MutationWith Brain and/or Leptomeningeal MetastasisFailed Tyrosine Kinase Inhibitors
Samsung Medical Center 80
Not applicableStudy completedNCT01721252
What this trial is testing

Tarceva. ICORG 08-41

Who this might be right for
Non-small Cell Lung Cancer
Cancer Trials Ireland 200
Testing effectiveness (Phase 2)Looking for participantsNCT05215548
What this trial is testing

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

Who this might be right for
NSCLC Stage IV
National Taiwan University Hospital 100
Early research (Phase 1)Study completedNCT02529995
What this trial is testing

Phase I, Study in Chinese NSCLC Patients

Who this might be right for
Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive
AstraZeneca 31
Testing effectiveness (Phase 2)Active Not RecruitingNCT03909334
What this trial is testing

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationAdvanced Cancer+1 more
Xiuning Le 160
Not applicableEnded earlyNCT00657098
What this trial is testing

Side Effects of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) Directed Therapy

Who this might be right for
Metastatic Malignancies
University Medical Center Groningen 73
Testing effectiveness (Phase 2)Study completedNCT01198028
What this trial is testing

Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma

Who this might be right for
Metastatic Skin Squamous Cell CarcinomaRecurrent Skin Squamous Cell Carcinoma
M.D. Anderson Cancer Center 42
Large-scale testing (Phase 3)Looking for participantsNCT05852990
What this trial is testing

Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC

Who this might be right for
Non-Small Cell Lung Cancer With EGFR Mutation
Instituto Nacional de Cancerologia de Mexico 28
Testing effectiveness (Phase 2)Study completedNCT01573702
What this trial is testing

Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)

Who this might be right for
Non Small Cell Lung Cancer
UNC Lineberger Comprehensive Cancer Center 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT03586453
What this trial is testing

Osimertinib In EGFR Mutant Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Dana-Farber Cancer Institute 30
Early research (Phase 1)Active Not RecruitingNCT02503722
What this trial is testing

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage III Lung Non-Small Cell Cancer AJCC v7+3 more
National Cancer Institute (NCI) 36
Large-scale testing (Phase 3)UnknownNCT03727867
What this trial is testing

Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer

Who this might be right for
Advanced Non-small Cell Lung Cancer
Haihua Yang 300
Testing effectiveness (Phase 2)Study completedNCT04147351
What this trial is testing

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

Who this might be right for
NSCLC Stage IIIB~IV
National Taiwan University Hospital 22
Large-scale testing (Phase 3)Study completedNCT02151981
What this trial is testing

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Anticancer Treatment
AstraZeneca 421